Mabpharm Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Mabpharm does not have a record of paying a dividend.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Rückkaufsrendite

Gesamte Aktionärsrendite	n/a
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if 2181's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if 2181's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

Mabpharm Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von 2181 im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (2181)	n/a
Untere 25 % des Marktes (HK)	3.2%
Markt Top 25 % (HK)	7.9%
Branchendurchschnitt (Biotechs)	1.1%
Analystenprognose (2181) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Unable to evaluate 2181's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate 2181's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate 2181's payout ratio to determine if its dividend payments are covered by earnings.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as 2181 has not reported any payouts.

Mabpharm Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.024 loss in 1H 2023)

Mabpharm Limited to Report First Half, 2024 Results on Aug 28, 2024

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection)

Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Mabpharm Limited, Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.051 loss in FY 2022)

Mabpharm Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm Limited Announces Director Changes

First half 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.028 loss in 1H 2022)

Mabpharm Limited to Report First Half, 2023 Results on Aug 25, 2023

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.071 loss in FY 2021)

Less than half of directors are independent

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Mabpharm Limited to Report First Half, 2022 Results on Aug 26, 2022

Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis

Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017

Less than half of directors are independent

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

First half 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.013 loss in 1H 2020)

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$1.18

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

New 90-day low: HK$1.08

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

New 90-day low: HK$1.14

Mabpharm Limited Announces CEO Changes

New 90-day low: HK$1.15

Mabpharm Limited to Report First Half, 2020 Results on Aug 26, 2020

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen